Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Dementia & Alzheimer’s — Weekly Report — October 26, 2026

Home/Health Insights/Dementia & Alzheimer's — October 26 – November 2, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Dementia & Alzheimer's
Updated Monday · November 16, 2026
Dementia & Alzheimer's · October 26 – November 2, 2026

Dementia & Alzheimer's
Weekly Report

This week's data 10 new clinical trials registered across 7 countries, with 959 trials actively recruiting patients worldwide.
Week of October 26 – November 2, 2026
  • 10 new clinical trials registered across 7 countries.
  • 959 trials actively recruiting patients worldwide.
  • Notable trial: The Efficacy of an IADL-based Non-immersive Virtual Reality Training Program to Enhance ADL Performance and Cognitive... (216 patients).
  • 1,735 new research papers published.
  • Top cited: "Annual Wellness Visits and Timing of Advance Care Planning Among Medicare Beneficiaries With Cogn..." (Journal of the American Geriatrics Society, 2 citations).
  • Drug safety: Most reported effect across tracked medications (donepezil, memantine, rivastigmine, galantamine, lecanemab) was Death.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 26 – November 2, 2026
New Trials This Week
10.
registered Oct 26–Nov 2
Recruiting Now
959
active trials seeking patients
Countries
7
with active trials this week
Papers Published
1,735
new studies this week
Phase 3 Trials
0
late-stage trials this week
Fig. 01

Trials by country

Count · October 26 – November 2, 2026
Not specified
2
Canada
2
China
2
Spain
2
Italy
1
Belgium
1
Taiwan
1
0 1 2
total
Fig. 02

Trials by phase

Distribution · October 26 – November 2, 2026

New clinical trials registered this week for Dementia & Alzheimer's. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

10 trials registered for Dementia & Alzheimer's. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models Dementia & Alzheimer's · Istituti Clinici Scientifici Maugeri SpA (NCT07906769) Other Recruiting 200 Italy
02 Network-based tDCS for Apathy Dementia & Alzheimer's · Hebrew SeniorLife (NCT07900191) Other Not Yet Recruiting 20 N/A
03 Virtual Reality to Advance Dementia Care and Quality of Life Dementia & Alzheimer's · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (NCT07893678) Other Not Yet Recruiting 10 Canada
04 Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease Dementia & Alzheimer's · Universitaire Ziekenhuizen KU Leuven (NCT07906054) Other Not Yet Recruiting 70 Belgium
05 Effects of Doll Therapy on Apathy and Activities of Daily Living Initiation Deficits in Older Adults With Dementia Dementia & Alzheimer's · Xinyu ZHANG (NCT07907042) Other Recruiting 106 China
06 A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease Dementia & Alzheimer's · Vigonvita Life Sciences (NCT07905352) Phase 2 Not Yet Recruiting 200 China
07 A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults Dementia & Alzheimer's · Pfizer (NCT07897708) Phase 1 Not Yet Recruiting 98 N/A
08 The Efficacy of an IADL-based Non-immersive Virtual Reality Training Program to Enhance ADL Performance and Cognitive Function for Persons at Risk of Dementia Dementia & Alzheimer's · National Taiwan University Hospital (NCT07895979) Other Recruiting 216 Taiwan
09 Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease Dementia & Alzheimer's · Universidad de Burgos (NCT07902206) Other Not Yet Recruiting 88 Spain
10 Feasibility of Community Occupational Therapy for Dementia (COT-D) Dementia & Alzheimer's · University of Vic - Central University of Catalonia (NCT07905872) Other Not Yet Recruiting 48 Spain
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Dementia & Alzheimer's. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
donepezil Death 208
memantine Death 129
rivastigmine Death 292
galantamine Fall 32
lecanemab Amyloid Related Imaging Abnormality-oedema/effusion 202

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Dementia & Alzheimer's. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

1,735 papers

Recently published peer-reviewed studies related to Dementia & Alzheimer's, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Operational end-of-life trajectory categories among patients who died in the emergency department: associations with resuscitative and palliative care in a five-year retrospective cohort. Spampinato MD et al. 10.1007/s11739-026-04578-6
View abstract

BACKGROUND: Emergency departments (EDs) increasingly care for patients approaching the end of life, yet the relationships between patterns of decline and final ED care remain poorly characterised. The objective was to describe the distribution of retrospectively assigned trajectory-oriented categories among ED decedents and examine associations with care processes. METHODS: This single-centre retrospective cohort study included adults who died in the ED between 2018 and 2022. Categories were acute event/low comorbidity (T1), terminal malignancy or pre-existing exclusive palliative/comfort-focused care (T2), advanced chronic disease with acute decompensation (T3), frailty/dementia or high comorbidity with severe functional dependency (T4), and residual unclassified cases (T5). Primary outcomes were CPR and documented initiation of exclusive palliative/comfort-focused care; documented end-of-life recognition or discussion was secondary. RESULTS: Of 628 patients, 1.3% were T1, 10.8% T2, 10.0% T3, 49.4% T4, and 28.5% T5. CPR ranged from 75% in T1 to 24% in T2 and T4 (p<0.001). Exclusive palliative/comfort-focused care was initiated in 35% of T2 and 11% of T3-T5 patients (p<0.001). End-of-life recognition or discussion ranged from 12% in T1 to 51% in T2 (p=0.034). CONCLUSION: Frailty and dementia represented the main trajectory of death in the ED, while nearly one-third of patients could not be classified within the predefined categories. A pragmatic trajectory-oriented framework may help interpret observed patterns of care. However, retrospective assignment and the large residual group make these findings hypothesis-generating; prospective validation is required before decision-support use.

Internal and emergency medicine 2026 Nov 1 PubMed
02 Targeting RIPK1-NF-κB crosstalk: A novel perspective on necroptosis in Alzheimer's Disease. Kartik S et al. 10.1007/s11033-026-13067-0
View abstract

Alzheimer's disease (AD) is a progressive neurodegenerative condition characterised by gradual neuronal degradation, resulting in cognitive decline and memory loss. Multiple pathogenic mechanisms drive the progression of the disease, including amyloid-β (Aβ) and tau accumulation (neurofibrillary tangles), mitochondrial dysfunction, synaptic loss, chronic neuroinflammation, and neuro​nal death. Neuronal loss in AD occurs through various forms of regulated cell death, including apoptosis, ferroptosis, pyroptosis, parthanatos, and necroptosis, each characterised by specific pathways and subsequent inflammatory consequences. Despite decades of focus on apoptosis and necrosis as the primary modes of neuronal loss, necroptosis has remained relatively understudied until recently. Necroptosis is a caspase-independent, inflammatory cell death pathway governed by the RIPK1-RIPK3-MLKL signalling axis. Activation of this pathway disrupts plasma membrane integrity, triggering the release of damage-associated molecular patterns (DAMPs) that sustain a self-propagating cycle of neuroinflammation and secondary neuronal loss. Crucially, RIPK1 signalling is closely linked to nuclear factor-[Formula: see text]B (NF-[Formula: see text]B), a principal modulator of inflammatory and cell-survival mechanisms. Although NF-[Formula: see text]B activation can facilitate neuronal survival under physiological conditions, its sustained activation in the AD brain promotes the synthesis of pro-inflammatory mediators, thereby accelerating neurodegeneration. This review discusses the emerging role of RIPK1-mediated necroptosis in AD and examines its functional interaction with NF-[Formula: see text]B signalling in driving neuroinflammation. Additionally, it examines emerging therapeutic strategies targeting the RIPK1-NF-[Formula: see text]B axis to alter disease progression and achieve disease-modifying potential in AD.

Molecular biology reports 2026 Nov 1 PubMed
03 The "Invisible Killer" of Neurodegeneration: Mitochondrial Dysfunction in Neurodegenerative Disorders, Mechanisms, Emerging Pathways and Therapeutic Strategies. Cao S et al. 10.2147/JIR.S653025
View abstract

Neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) place substantial burden on global public health. Mounting evidence identifies mitochondrial dysfunction as a central contributor to neuronal damage and progressive brain functional decline. As a narrative review, this work aims to dissect mitochondrial‑associated pathological features across these major neurodegenerative disorders, summarize under‑recognized emerging mechanisms, and highlight translational bottlenecks for mitochondrial‑targeted therapies. Mitochondria sustain neuronal survival by mediating oxidative‑phosphorylation‑driven energy production, biomolecule biosynthesis, calcium homeostasis, reactive oxygen species (ROS) metabolism, and apoptotic regulation. In PD, aggregated α‑synuclein (α‑syn) damages respiratory‑chain complex I, perturbs mitochondrial dynamics and blocks PINK1/Parkin‑dependent mitophagy. In AD, amyloid‑β together with hyper‑phosphorylated tau (p-Tau) impairs respiratory complex activity, axonal mitochondrial trafficking and mitophagic clearance. Mutant huntingtin induces multiple mitochondrial lesions in HD, while inflammation‑triggered oxidative stress secondarily compromises mitochondrial function in MS. Pathogenic mutations in ALS disrupt respiratory‑chain assembly, mitochondrial dynamics and mitophagy. Beyond classic mitochondrial defects including respiratory‑chain impairment, dynamic imbalance and defective mitophagy, emerging mechanisms such as mitocytosis, mitochondrial aminoacyl‑tRNA synthetase (mt‑aaRS) dysfunction and mitochondria‑associated membrane (MAM) disruption are discussed. Mitochondrial dysfunction drives neurodegeneration via energy exhaustion, aggravated oxidative stress, pathological protein aggregation and excessive neuronal apoptosis. We further recapitulate mitochondrial‑oriented therapeutic approaches including small‑molecule regulators, mitophagy activators, mitochondrial biogenesis promoters, gene‑editing strategies and mitochondrial transplantation. Notable translational obstacles remain, including limited blood‑brain‑barrier penetration of candidate drugs, narrow therapeutic time‑window post‑symptom onset, and prominent disease heterogeneity. By synthesizing basic experimental findings and pre‑clinical and clinical trial progress, this review provides updated insights into the pathogenesis of neurodegenerative diseases and facilitates the development of precise mitochondrial‑targeted therapeutic regimens.

Journal of inflammation research 2026 PubMed
04 Mini-Mental State Examination trajectories across dementia subtypes in the Swedish Registry for Cognitive/Dementia Disorders and U.S. National Alzheimer's Coordinating Center. Bao X et al. 10.1002/dad2.70531
View abstract

INTRODUCTION: Mini-Mental State Examination (MMSE) trajectories are widely used to describe cognitive decline in dementia, but estimates may be sensitive to cohort structure, follow-up density, and modeling assumptions. We compared subtype-specific MMSE trajectories across two complementary longitudinal data resources. METHODS: The analyzed data were from the Swedish Registry for Cognitive/Dementia Disorders (SveDem) and the U.S. National Alzheimer's Coordinating Center (NACC). Participants were included with at least two valid cognitive assessments separated by ≥ 90 days. The final cohorts included 30,115 SveDem participants and 33,429 NACC participants. Subtype-stratified regression-spline generalized additive mixed models and linear mixed-effects models were fitted with adjustment for demographic and clinical covariates. RESULTS: Compared with NACC, SveDem participants were older (median age 79 vs. 72 years), had lower baseline MMSE scores (22.3 ± 4.2 vs. 26.5 ± 4.6), and had shorter follow-up (median 1.9 vs. 3.2 years; mean cognitive assessments 2.9 vs. 4.5). Shared dementia subtypes showed broadly similar relative decline patterns across cohorts. In regression-spline models, Alzheimer's disease showed faster estimated annualized decline than vascular dementia in both SveDem (-0.79 vs. -0.49 MMSE points/year) and NACC (-1.22 vs. -0.24 points/year). Lewy body dementias and frontotemporal dementia showed intermediate but less consistent patterns. Absolute decline estimates varied by model specification, particularly where later follow-up was sparse. DISCUSSION: Relative subtype-specific MMSE decline patterns were broadly reproducible, whereas absolute long-horizon estimates required cautious interpretation. These cross-cohort reference patterns may support future dementia epidemiology studies using MMSE trajectories to compare subtypes, examine clinical factors or evaluate treatment-related associations.

Alzheimer's & dementia (Amsterdam, Netherlands) 2026 Oct-Dec PubMed
05 Spatial patterns of amyloid clearance after donanemab: A preliminary 12-month real-world amyloid PET study in Japanese patients with early Alzheimer's disease. Kujuro Y et al. 10.1002/dad2.70539
View abstract

INTRODUCTION: The regional pattern of amyloid clearance during donanemab treatment in routine practice is poorly characterized. METHODS: We analyzed amyloid positron emission tomography (Centiloid, regional standardized uptake value ratio, visual reads) at baseline and 12 months in 18 donanemab-treated patients with early Alzheimer's disease. RESULTS: Clearance was near-complete (removal 96%; 72% visually negative, i.e., full treatment-related amyloid clearance), although lower in the 2 early-onset (78%) than the 16 late-onset patients (98%). Higher baseline burden and older age predicted greater clearance ( 0.88,  .001;  0.60,  .009, respectively). This held regionally ( 0.82-0.91, all  .001), with the posterior cingulate and precuneus clearing first. Clearance was independent of medial temporal atrophy and unrelated to 12-month cognitive change. DISCUSSION: Donanemab cleared regional amyloid in proportion to its baseline distribution, with deposition-heavy regions clearing first and the temporal cortex retaining residual signal, independent of neurodegenerative stage and unrelated to short-term cognition.

Alzheimer's & dementia (Amsterdam, Netherlands) 2026 Oct-Dec PubMed
06 Communication and shared decision-making for anti-amyloid therapy in early Alzheimer's disease: An exploratory qualitative study of real-world audio-recorded clinical encounters. Paladino J et al. 10.1002/trc2.70343
View abstract

INTRODUCTION: Anti-amyloid therapies (AATs) for Alzheimer's disease (AD) offer modest slowing of cognitive decline but involve meaningful risks, burdens, and uncertainty. Decisions about AAT are preference sensitive and optimally guided by shared decision making (SDM), yet little is known about how these conversations unfold in real-world clinical practice. METHODS: We conducted an exploratory qualitative content analysis of audio-recorded AAT counseling encounters in neurology clinics at two academic medical centers. Participants included neurology clinicians, patients with mild cognitive impairment or mild dementia due to AD, and care partners. We examined how clinicians presented options, benefits, risks, and burdens; elicited patient values and preferences; assessed understanding; and engaged patients and care partners. RESULTS: We analyzed 10 encounters involving 9 patients and 5 clinicians; 8 patients had a care partner present. Encounters occurred at different stages of decision making, including pre-decision visits and visits in which a treatment decision was made. Clinicians consistently explained AAT mechanisms using action-oriented language, emphasized modest benefits, and discussed amyloid-related imaging abnormalities, magnetic resonance imaging monitoring as a safety net, and treatment logistics. However, communication framing varied. Some clinicians used optimistic framing that may have shaped treatment perceptions, while explicit discussion of not pursuing AAT as a valid option was rare. Open-ended exploration of values and goals varied and occurred more often in pre-decision encounters, whereas visits closer to treatment decisions focused on treatment selection and logistics. Assessment of treatment understanding ranged from open-ended teach-back, which revealed misunderstandings in some cases, to closed-ended checks. Clinicians also varied in how they balanced patient and care partner participation. DISCUSSION: Although clinicians consistently addressed core medical information about AAT, variation in framing, values elicitation, teach-back, presentation of alternatives, and patient-care partner engagement may shape AAT decision making. Communication strategies that explicitly present options, connect potential outcomes to patient priorities, and reinforce understanding may support balanced, values-aligned SDM.

Alzheimer's & dementia (New York, N. Y.) 2026 Oct-Dec PubMed
07 Cross-Organ Multi-Omics Profiling of Systemic Alterations in 5xFAD Mice and Changes Associated with Huanglian Jiedu Decoction Treatment. Gao W et al. 10.1002/advs.78442
View abstract

Alzheimer's disease (AD) is increasingly recognized as a systemic disorder involving metabolic abnormalities beyond the brain, but links between hepatic alterations and neuroinflammation remain unclear. We integrated behavioral, histopathological, transcriptomic, proteomic, phosphoproteomic, and metabolomic analyses in male mice assigned to WT (n = 15), AD (n = 16), high-dose HLJDD (n = 16), low-dose HLJDD (n = 11), and donepezil (n = 10) groups and treated for 10 weeks. Longitudinal behavioral data were analyzed using repeated-measures models, and omics p-values were adjusted using the Benjamini-Hochberg FDR procedure. Cognitive impairment, glial activation, and neuroinflammation were accompanied by hepatic metabolic disturbances and alterations in insulin signaling and energy metabolism, implicating PPAR and PI3K/Akt-related processes. HLJDD, particularly at the high dose, improved behavioral and neuropathological outcomes and shifted abnormalities in TCA-cycle metabolites, amino acid neurotransmitters, and oxidative balance toward WT levels. To assess hepatocyte contributions to microglial inflammation, we established an AML12-BV2 conditioned-medium model with hepatocyte PPAR-γ knockdown. Conditioned medium from LPS/HLJDD-cotreated AML12 cells elicited lower inflammatory responses in BV2 cells than medium from LPS-treated hepatocytes. PPAR-γ knockdown attenuated this effect, supporting a hepatocyte PPAR-γ-dependent contribution to microglial regulation and further investigation of hepatic involvement in HLJDD-associated neuroprotection.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Oct 31 PubMed
08 Management of acute situations in institutionalised Parkinsonian patients: A survey in Seine-Saint-Denis, France. Braccagni L et al. 10.1016/j.neurol.2026.10.003
View abstract

OBJECTIVE: Patients with Parkinson's disease (PD) or atypical parkinsonian syndromes (PS) living in long-term care facilities face complex medical needs, yet little is known about their medical follow-up and reasons for emergency department referrals and hospitalisations in this setting. This study aimed to describe the prevalence of PD/PS among residents of long-term care facilities (EHPADs) in the French Seine-Saint-Denis department, their medical follow-up, and the frequency and reasons for emergency department referrals and hospitalisations. METHODS: This retrospective study covered the year 2023. All 66 EHPADs in the department were contacted to complete a facility-level questionnaire on PD/PS prevalence and emergency referrals. Facilities with PD/PS residents were then invited to complete a patient-level questionnaire collecting demographic, clinical and follow-up data, and details regarding emergency referrals and hospitalisations. RESULTS: Thirty-five EHPADs (53%) responded, representing 3398 residents. Thirty facilities reported 144 residents with PD or PS, corresponding to a prevalence of 4.24% [95% CI: 3.60-4.98%]. Sixteen (53.3%) EHPADs reported at least one PD/PS resident referred to the emergency department, resulting in 62 referrals during the year, corresponding to an incidence rate of 0.43 [95% CI: 0.33-0.55] referrals per PD/PS resident-year. Eight EHPADs (26.7%) completed the patient-level questionnaire, providing data on 34 residents (median [Q1-Q3] age: 80 [75-85], 73.5% with PD). Over one-third (38.2%) did not have a designated neurologist during 2023. Nine patients (27.3%) were referred to the emergency department, mainly for axial disorders (33.3%) and infections (33.3%). Nine patients (26.5%) were hospitalised. Exploratory analyses showed that hospitalisation was significantly associated with emergency referral (P=0.02) and a last general practitioner consultation that was less often for routine care (P=0.048). CONCLUSION: PD and PS were frequently identified among residents of participating EHPADs, yet a substantial proportion of patients lack neurological follow-up. Emergency referrals and hospitalisations affected approximately one-quarter of patients, often for potentially preventable causes. These findings suggest that preventive strategies, multidisciplinary follow-up, and improved access to neurologists may help reduce avoidable hospitalisations.

Revue neurologique 2026 Oct 31 PubMed
09 Current development of therapeutic strategies for Alzheimer's disease. Goetzl EJ 10.1016/j.amjmed.2026.10.031
View abstract

Alzheimer's disease is an increasingly prevalent neurodegenerative cause of dementia. The prevailing model begins with neuronal deposits of beta-amyloid (Aβ42) (phase I), followed by intra-neuronal fibrillary tangles of p-tau (phase II) that recruit numerous effector pathways (phase III) leading to neuronal damage, synaptic loss and gliosis. Monoclonal anti-Aβ antibodies and tau substituent peptide-elicited anti-p-tau antibodies reduce brain loads of these pathogenic proteins. Anti-Aβ antibodies decreased cognitive loss by a mean of 26%, but anti-p-tau antibodies had no effect. Anti-p-tau antibodies were well-tolerated, but 30% of patients receiving anti-Aβ antibodies had brain areas of swelling and hemorrhages detected by imaging. Early studies of pharmacological alteration of phase III neuropathic effector mechanisms in humans and mouse models include inhibition of intersectin-1 to preserve mitophagy and synaptic vesicle recycling, melanin-concentrating hormone prevention of memory loss, chimeric (brain astrocyte) antigen-astrocyte reduction in Aβ load, PD-1 immune checkpoint inhibitor suppression of neuroinflammation, and reduction in oxidative stress by phytochemicals or MitoVitE. The many possible mechanisms of decreased resilience of neurons to effector attacks of Alzheimer's disease remain under investigation.

The American journal of medicine 2026 Oct 31 PubMed
10 Dendrobium officinale extract ameliorates Alzheimer's disease by modulating PI3K-AKT-mTOR pathway and autophagy-related processes: An integrated study combining feature-based molecular networking, network pharmacology and multi-omics. Fu J et al. 10.1016/j.jep.2026.122588
View abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with limited effective treatments. Dendrobium officinale Kimura & Migo (D. officinale) has been traditionally used for dementia, but its active constituents and mechanisms remain unclear. AIM OF THE STUDY: This study aimed to systematically characterize the chemical constituents of D. officinale extract (DOE) and elucidate its anti-AD mechanisms using an integrated pharmacological strategy. MATERIALS AND METHODS: The chemical composition of DOE was analyzed using UHPLC-Q-TOF/MS combined with feature-based molecular networking (FBMN). Target prediction and pathway analysis were performed using a network pharmacology approach. Therapeutic effects were evaluated in 5×FAD mice using behavioral and histopathological assays. Mechanistic validation was further conducted using transcriptomics, proteomics, qRT-PCR, Western blotting, and molecular docking. RESULTS: Sixty-five components were identified, with apigenin, naringenin, rutin and oxyresveratrol as major identified constituents. Integrated multi-omics and network pharmacology analyses highlighted the PI3K-AKT-mTOR pathway and autophagy-related processes as potential mechanisms underlying the anti-AD effects of DOE. In 5×FAD mice, DOE markedly improved cognitive deficits, alleviated hippocampal neuronal injury, reduced Aβ plaque deposition, and suppressed astrocytic and microglial activation. Mechanistically, DOE significantly downregulated the mRNA expression of Pi3k, Akt, and Mtor, reduced AKT and mTOR phosphorylation, and showed a trend toward decreased PI3K phosphorylation. DOE also reduced p62 accumulation and increased the LC3-II/LC3-I ratio, suggesting an improvement in autophagy-related processes. Molecular docking further demonstrated favorable binding affinities of major identified constituents toward key targets, particularly AKT1 and PIK3CA. CONCLUSION: DOE ameliorates AD-related pathological changes, potentially through modulation of the PI3K-AKT-mTOR pathway and improvement of autophagy-related processes. These findings provide experimental evidence supporting the potential of D. officinale as a multi-target therapeutic candidate for AD.

Journal of ethnopharmacology 2026 Oct 31 PubMed
11 SIRT1 Signaling in Alzheimer's Disease: Regulation of Mitochondrial Biogenesis and Therapeutic Implications. Liu D et al. 10.1016/j.phrs.2026.109713
View abstract

Alzheimer's disease (AD) is one of the leading causes of dementia worldwide. Its pathological features include Aβ deposition, Tau hyperphosphorylation, and impaired neuronal energy metabolism, accompanied by persistent oxidative stress. As a nicotinamide adenine dinucleotide (NAD)-dependent deacetylase, sirtuin 1 (SIRT1) is a central regulator of mitochondrial biogenesis. This review systematically examines the emerging roles of SIRT1 in regulating these pathological processes in AD, with a particular focus on its regulation of mitochondrial biogenesis. It also delineates the complex regulatory mechanisms governing SIRT1, including NAD-metabolism-dependent regulation, protein interaction-dependent regulation, post-translational modifications such as ISGylation and nitrosylation, and non-coding RNA-mediated post-transcriptional regulation. In addition, the coordinated influence of upstream activators and downstream effectors is discussed. Impairment of SIRT1-mediated mitochondrial biogenesis may exacerbate neuronal energy deficits and oxidative stress in AD, thereby increasing susceptibility to neurodegeneration. This review further elucidates the molecular mechanisms underlying the SIRT1-mitochondrial biogenesis axis. By integrating upstream activating signals with downstream effectors, SIRT1 creates a permissive regulatory environment for peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)-driven, mitochondrial transcription factor A (TFAM)-mediated mitochondrial biogenesis, thereby facilitating quality-controlled renewal of the mitochondrial network. In addition, this review discusses the potential value of dynamic biomarker monitoring following therapeutic targeting of the SIRT1 pathway and summarizes current challenges and future intervention strategies. Targeting SIRT1-mediated mitochondrial biogenesis may provide a promising avenue for the development of novel therapeutic strategies for AD.

Pharmacological research 2026 Oct 31 PubMed
12 Nanomedicine for Alzheimer's Disease: A Stage-Matched Framework Integrating Pathological Network Modulation, Blood-Brain Barrier Delivery, and Clinical Translation. Li J et al. 10.1016/j.phrs.2026.109709
View abstract

Alzheimer's disease (AD) remains one of the most difficult neurodegenerative disorders to treat. Therapeutic failure is driven mainly by two barriers: the multifactorial pathological network of AD and the limited access of most therapeutics to the brain imposed by the blood-brain barrier (BBB). Conventional symptomatic drugs and emerging antibody-based therapies provide clinical benefit, but they do not fully address the interacting processes involving amyloid-β (Aβ) accumulation, Tau pathology, neuroinflammation, mitochondrial dysfunction, oxidative stress, and synaptic impairment. In this review, we discuss nanomedicine as an integrated platform for AD intervention. We summarize the major pathological nodes that provide targets for nanomedicine-based therapy and discuss BBB structure and transport mechanisms. We then compare polymeric, inorganic, carbon-based, lipid-based, protein-based, nucleic acid-based, and biomimetic platforms in terms of delivery function, intrinsic bioactivity, pathological modulation, and translational risk. Assisted brain-delivery strategies are also discussed, including focused ultrasound-mediated BBB modulation and intranasal nose-to-brain delivery. We then review clinical-stage AD nanomedicine candidates and summarize the key barriers to their translation. This review integrates stage-dependent pathology, BBB transport, and nanoplatform properties. It proposes a stage-matched framework for preclinical, mild symptomatic, and moderate-severe AD. At each stage, the framework matches active pathological nodes with feasible BBB transport strategies, carrier features, and administration routes. It may guide the development of mechanistically defined, reproducible, and clinically testable nanomedicines.

Pharmacological research 2026 Oct 31 PubMed
13 Reduced BNIP1 impairs autophagosome-lysosome fusion in hippocampal neurons and contributes to Alzheimer's disease pathology. Li C et al. 10.1016/j.brainresbull.2026.112186
View abstract

BNIP1 (BCL2‑interacting protein 1) belongs to the soluble N‑ethylmaleimide‑sensitive factor attachment protein receptor (SNARE) family. Statistical screening based on the Gene Expression Omnibus (GEO) dataset GSE48350 reveals reduced BNIP1 expression in patients with Alzheimer's disease (AD), suggesting that BNIP1 is a potentially key regulatory protein for investigating AD pathogenesis. In this study, we detected BNIP1 protein levels in APP/PS1 transgenic mice and APP‑overexpressing HT22 hippocampal neuronal cells, screened key interacting proteins of BNIP1 via mass spectrometry, and further performed gain‑ and loss‑of‑function assays using overexpression plasmids and small interfering RNA (siRNA) to verify the protein function of BNIP1. Our findings indicate that, in these experimental models, reduced BNIP1 expression contributes to AD‑related pathological alterations by impairing autophagosome‑lysosome fusion. Restoration of BNIP1 expression enhances Rab5b‑mediated Rab7 recruitment and consequently ameliorates autophagosome‑lysosome fusion. This study suggests that reduced BNIP1 expression is involved in AD‑related pathological alterations.NIP1 (BCL2-interacting protein 1) belongs to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) family. Statistical screening based on the Gene Expression Omnibus (GEO) dataset GSE48350 reveals reduced BNIP1 expression in Alzheimer's disease (AD) patients, which renders BNIP1 a potentially key regulatory protein for investigating AD pathogenesis. In this study, we detected BNIP1 protein levels in APP/PS1 transgenic mice and APP-overexpressing HT22 hippocampal neuronal cells. Mass-spectrometry analysis was performed to screen key interacting proteins of BNIP1. Gain- and loss-of-function experiments were further conducted using overexpression plasmids and small interfering RNAs (siRNAs) to verify the protein function of BNIP1. Our findings indicate that decreased BNIP1 may act as an important contributing factor mediating AD-associated autophagosome-lysosome fusion defects in these experimental models. Restoration of BNIP1 expression enhances Rab5b-mediated Rab7 recruitment and consequently ameliorates aberrant autophagosome-lysosome fusion. This study suggests that BNIP1 serves as a potentially key regulatory protein for mechanistic research into Alzheimer's disease.

Brain research bulletin 2026 Oct 31 PubMed
14 Promoting resilience in primary caregivers of people with dementia through health programmes: a systematic review. Loma-Ramos S et al. 10.1016/j.gerinurse.2026.104426
View abstract

BACKGROUND: Given dementia's global public health impact and the substantial burden borne by family caregivers, there is a need to shift from deficit-focused models towards understanding and promoting caregiver resilience as a dynamic protective process. OBJECTIVE: To synthesise the available evidence on the influence of support programmes on resilience among family caregivers of people with dementia. INFORMATION SOURCES: Four electronic databases (WoS, Scopus, PubMed y CINAHL) covering peer-reviewed literature published between 2015 and 2025. METHODS: A systematic review was reported in accord with the PRISMA reporting guidelines and a PROSPERO-registered protocol, independent study selection and data extraction, quality appraisal using JBI tools, and a narrative synthesis of findings applying the SWiM approach and thematic analysis. RESULTS: A total of 21 studies published between 2015 and 2025 were included. The intervention studies evaluated mindfulness-based, psychoeducational, counselling, cognitive-behavioural, arts-based, and peer-support programmes. Several studies reported improvements in resilience or related caregiver outcomes, including burden, psychological distress, coping, and quality of life, although results varied across interventions and study designs. Complementary observational, qualitative, and measurement evidence identified self-efficacy, adaptive coping, social support, and relationship quality as mechanisms relevant to programme influence, whereas behavioural and neuropsychiatric symptoms of the person with dementia were associated with lower resilience. Sustained follow-up appeared relevant to maintaining programme-related benefits. CONCLUSIONS: Support programmes may strengthen resilience and improve related health and well-being outcomes among family caregivers of people with dementia, particularly when they include psychoeducational, counselling, mindfulness-based, or sustained follow-up components. However, the heterogeneity of interventions and study designs limits firm conclusions regarding their effectiveness. REGISTRATION: This study was registered in PROSPERO (CRD42024550450) SOCIAL MEDIA ABSTRACT: A systematic review (2015-2025) suggests that support programmes may strengthen resilience and related well-being among family caregivers of people with dementia, although effects vary across interventions.

Geriatric nursing (New York, N.Y.) 2026 Oct 31 PubMed
15 Cognitive subtypes of Parkinson's disease patients with cognitive impairment and implications for geriatric nursing interventions: A latent profile analysis. Hou Y et al. 10.1016/j.gerinurse.2026.104419
View abstract

OBJECTIVES: To identify cognitive subtypes in Parkinson's disease patients with cognitive impairment (PD-CI) and explore their influencing factors, so as to provide empirical evidence for targeted geriatric nursing interventions. METHODS: This cross-sectional study recruited PD-CI patients using convenience sampling from August 2022 to July 2025. Data were collected using a demographic questionnaire, the Beijing version of the Montreal Cognitive Assessment (MoCA-BJ), Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III), modified Hoehn and Yahr scale (modified HY), and Activities of Daily Living Scale (ADL). Latent profile analysis (LPA) identified cognitive subtypes, and univariate and multivariate logistic regression explored influencing factors. RESULTS: A total of 246 PD-CI patients were included. LPA identified three cognitive profiles: high cognition-isolated memory decline group (class 1, n=161, 65.4 %), moderate cognition-multi-domain impairment group (class 2, n=64, 26.1 %), low cognition-dementia high risk group (class 3, n=21, 8.5 %).Class 1 had the best overall cognition, with isolated memory decline. Class 2 presented multi-domain impairments (abstraction, memory, visuospatial/executive functions) and significantly worse ADL than Class 1. Class 3 showed the most severe overall cognitive decline, particularly in visuospatial/executive functions and attention, with concurrent ADL and motor deterioration. CONCLUSIONS: PD-CI patients show heterogeneous cognitive subtypes with distinct nursing needs. Class 1 requires memory support and safety education; Class 2 needs comprehensive ADL assistance; Class 3 demands proactive integrated management of cognitive, ADL, and motor decline with robust caregiver support. These findings inform personalized geriatric nursing for PD-CI patients.

Geriatric nursing (New York, N.Y.) 2026 Oct 31 PubMed
16 Length of stay by restraint type in hospital dementia care: A retrospective analysis of nursing flowsheet data. Shaw CA et al. 10.1016/j.gerinurse.2026.104410
View abstract

BACKGROUND: Restraint use in hospital dementia care contributes to poor outcomes. De-implementation efforts and national estimates have focused on traditional restraints such as wrist, ankle, and vest. Mitts and geri-chairs are not universally recognized as restraints despite meeting the accepted definition. The objective was to determine the differential impact of restraint types on length of stay in medical-surgical dementia care. METHODS: This retrospective analysis used nursing flowsheet data from the electronic medical record at one midwestern United States academic medical center from 2018 to 2022. The sample included 1987 hospitalizations of 1425 patients with dementia on medical-surgical units, excluding emergency, intensive care, and psychiatric units. Restraints were categorized as traditional (wrist, ankle, vest, elbow, belt), non-traditional (mitts, geri-chairs), or no restraints. A linear mixed effects model analyzed the association between restraint type and length of stay adjusting for demographic variables, clinical factors, and nursing care practices. RESULTS: Restraint use occurred in 21.0% of hospitalizations. Non-traditional restraints alone were most common (42.0%), followed by combined use (41.2%) and traditional restraints alone (16.8%); mitts were the most frequently used device (75.1%). Compared with no restraints, stays were 2.52 days longer with non-traditional restraints alone (95% CI=1.56-3.47) and 3.38 days longer with both types (95% CI=2.36-4.41). Non-traditional restraints alone were associated with 1.94 days longer stay than traditional restraints alone (95% CI=0.31-3.57). CONCLUSION: Non-traditional restraints were the most commonly used restraints in hospital dementia care and were associated with a meaningful impact on length of stay. Greater surveillance and de-implementation efforts are warranted.

Geriatric nursing (New York, N.Y.) 2026 Oct 31 PubMed
17 Immunometabolic dysregulation of reactive microglia and astrocytes in neurodegenerative diseases: Mechanistic insights and therapeutic implications. Gao C et al. 10.1016/j.jns.2026.126237
View abstract

Neurodegenerative diseases (NDDs) are increasingly understood as multifactorial disorders characterized by intertwined pathological processes, in which metabolic dysfunction may act as a critical and potentially disease-amplifying contributor to the proteinopathy-driven pathological cascade. Despite growing recognition that microglial and astrocytic metabolism governs central nervous system tissue damage-repair homeostasis, intercellular metabolic crosstalk between glia and neurons remains insufficiently synthesized across major NDDs. This review delineates how core metabolic pathways, including glycolysis, mitochondrial respiration, lipid processing, and amino acid transport, shape glial reactivity in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. We highlight glial metabolic reprogramming, a proposed theoretical framework arising from severe glial metabolic dysregulation. Within this framework, persistent pathological stress may drive reactive glia to sequester local energy substrates in excess, which is hypothesized to trigger bioenergetic failure in neighboring neurons. Broad-spectrum anti-inflammatory agents show poor clinical performance because they only block cytokine outputs rather than reverse glial metabolic exhaustion. Therapeutic efforts should therefore shift toward restoring glial metabolic flexibility. Cell-type-specific metabolic reprogramming, instead of pan-metabolic suppression, may circumvent systemic adverse effects. Precision strategies targeting such intercellular metabolic imbalance could provide promising cell-resolved metabolic avenues to retard NDD progression.

Journal of the neurological sciences 2026 Oct 28 PubMed
18 Safety vs Privacy: Ethical Dilemmas of Family Caregivers Using Smart Technologies for Dementia Care-Meta-Synthesis of Qualitative Research. Zhang J et al. 10.1016/j.jamda.2026.106509
View abstract

OBJECTIVES: Smart technologies are increasingly used in dementia home care to enhance safety. However, they may also generate profound ethical tensions by intruding upon privacy and autonomy. Family caregivers' experiences of navigating these tensions remain underexplored. This study aimed to synthesize qualitative evidence on family caregivers' experiences of ethical dilemmas arising from smart technology use in dementia home care. DESIGN: Meta-synthesis of qualitative studies. SETTING AND PARTICIPANTS: Family caregivers of community-dwelling persons with dementia who used or considered using smart technologies. METHODS: We searched 8 databases from inception to April 2026, supplemented by reference screening. We included qualitative studies or mixed-methods components reporting caregivers' ethical tension experiences. Two reviewers independently screened studies, extracted findings, and assessed quality using the Joanna Briggs Institute Critical Appraisal Checklist. Themes were integrated using Thomas and Harden's 3-stage thematic synthesis. RESULTS: A comprehensive search yielded 495 records, of which 10 studies met the inclusion criteria. The included studies were conducted across 7 countries or regions and involved 172 family caregivers, most of whom were female spouses or adult children. The integration of extracted content resulted in 3 themes: a persistent safety-privacy tension-balancing protection against respect for autonomy and dignity; an unresolved informed consent dilemma-stemming from fluctuating decision-making capacity vs continuous monitoring; relational disruption and trust erosion-particularly when devices malfunction or mismatch disease stage. CONCLUSIONS AND IMPLICATIONS: Caregivers face interconnected ethical dilemmas that are relational and situational. Future design and policy should prioritize transparent privacy safeguards, dynamic consent mechanisms that accommodate fluctuating capacity, and stage-aligned person-centered standards. These measures can help ensure that technologies genuinely support rather than undermine caregiving.

Journal of the American Medical Directors Association 2026 Oct 31 PubMed
19 Computationally driven design and validation of piperazine-bridged phthalimide derivatives as multifunctional agents against Alzheimer's disease. Devi B et al. 10.1016/j.ejmech.2026.119417
View abstract

A multi-target-directed ligand (MTDL) strategy has been proposed as an effective approach for treating complex multifactorial neurological disorders like Alzheimer's Disease. A 3D-QSAR pharmacophore model of piperazine derivatives against AChE was developed and validated (R = 0.99 and Q = 0.91). The best pharmacophore hypothesis model (AHR_1) was used to screen an in-house generated library of 188 phthalimide-piperazine derivatives, followed by structure-based virtual screening against the targeted enzymes. The docking scores of the identified eleven hit molecules were found to be better than the standard inhibitors, and MD simulations confirmed the stability of the compound-target complexes. As a proof of concept, the top hits were synthesized in the laboratory and evaluated for their inhibitory potential. Compound VPT-2 displayed IC values of 0.897 μM against AChE and 0.519 μM against MAO-B, while VPT-5 showed IC values of 3.45 μM against AChE and 1.074 μM against MAO-B, respectively. VPT-2 and VPT-5 inhibited Aβ self-aggregation significantly by 43.27 % and 43.28 %, respectively at a concentration of 20 μM, after 48 h. Additionally, an MTT assay using SH-SY5Y cells confirmed the safety of both the lead compounds up to 20 μM. Both compounds exhibited neuroprotective effects against 6-OHDA-induced neurotoxicity and significantly reduced intracellular ROS levels by 80-90 % at 5 μM. Thus, in this drug design strategy, CADD is integrated with in vitro experimental validation for the identification of phthalimide-piperazine derivatives as promising multi-target drug candidates for the treatment of Alzheimer's disease.

European journal of medicinal chemistry 2026 Oct 27 PubMed
20 CSF neurofilament, daily function, and survival correlates of a MOBP risk variant in the Barcelona PSP Registry: an exploratory study. Painous C et al. 10.1016/j.parkreldis.2026.109031
View abstract

OBJECTIVES: To investigate whether the PSP risk T-allele of the rs1768208 polymorphism at the MOBP locus is associated with neuroaxonal injury, as reflected by CSF levels of neurofilament light chain (CSF-NfL), and with exploratory clinical outcomes related to disease severity and progression. METHODS: We included patients from the Barcelona PSP Registry, a longitudinal, multicentre cohort. Participants underwent standardized clinical assessments, genetic testing, CSF-NfL determination, and longitudinal follow-up. Associations between MOBP rs1768208 genotype and CSF-NfL levels were evaluated using multivariable models adjusted for age, sex, and phenotype. Daily functioning (Schwab & England Activities of Daily Living, SEADL) and survival were explored as additional clinical outcomes. RESULTS: Carriers of the rs1768208 T-allele showed higher CSF-NfL levels in a dose-dependent manner and a higher likelihood of exceeding a clinically relevant CSF-NfL cut-off. Exploratory analyses showed associations of rs1768208 T/T homozygosity with worse functional status and shorter survival. DISCUSSION: This is the first study showing an in vivo association between a PSP genetic risk variant and a biomarker of neuroaxonal injury. Exploratory associations with clinical outcomes are aligned with the NfL association. If further confirmed, these findings could improve biological stratification and inform patient selection for, and interpretation of, clinical trials.

Parkinsonism & related disorders 2026 Oct 27 PubMed
21 Anatomical VOI-based assessment of the three DESH components in probable idiopathic normal pressure hydrocephalus. Takahashi R et al. 10.1007/s11604-026-02114-2
View abstract

PURPOSE: To evaluate whether anatomical volume-of-interest (VOI) thresholds derived from a SINPHONI-2 reference cohort could provide standardized component-wise quantification of disproportionately enlarged subarachnoid-space hydrocephalus (DESH) in a separate clinical cohort. MATERIALS AND METHODS: Thresholds were derived from 61 SINPHONI-2 cases using a prespecified mildest-case rule and applied without re-optimization to 33 participants with probable idiopathic normal pressure hydrocephalus (iNPH), 26 with Alzheimer disease, 18 with progressive supranuclear palsy, and 20 normal controls. DESH metric-S summed binary positivity for ventriculomegaly, Sylvian fissure enlargement, and tight high-convexity and medial sulci; DESH metric-I was defined as (Sylvian fissure volume + lateral ventricular volume)/high-convexity and medial sulcal volume. Evans index and callosal angle were evaluated as conventional imaging measures. RESULTS: For iNPH versus pooled non-iNPH, DESH metric-S had an area under the curve (AUC) of 0.958 (95% CI, 0.921-0.990), sensitivity of 97.0% (84.7-99.5%), and specificity of 92.2% (83.0-96.6%). DESH metric-I had an AUC of 0.995 (95% CI, 0.983-1.000), sensitivity of 100.0% (89.6-100.0%), and specificity of 93.8% (85.0-97.5%). CONCLUSION: Anatomical VOI-based measures provided standardized component-wise quantification of DESH morphology. DESH metric-S retained the status of each component, whereas DESH metric-I provided a continuous summary. Because DESH contributed to probable-iNPH classification, the observed discrimination reflects concordance with a DESH-supported classification rather than independent diagnostic accuracy for iNPH. External validation, including cohorts spanning incomplete/non-DESH morphology and treatment-response outcomes, is required before clinical or prognostic use.

Japanese journal of radiology 2026 Oct 31 PubMed
22 Intracerebral Administration of a Novel, Bioactive Peptide Induces a Biochemical Profile in Rat Brain Reminiscent of Alzheimer's Disease. Watkinson B et al. 10.1007/s11064-026-04944-y
View abstract

Alzheimer's disease (AD) presents a great unmet clinical need, but the much needed replication of the characteristic neuropathology in animal models has had limited success. Here, we provide in vivo evidence that T30, a bioactive peptide posited to drive AD, can induce in the rat brain a biochemical profile resembling AD pathology. Bilateral microinfusions of T30 into the medial septum/vertical diagonal band were administered twice a week for three weeks in rats. Although there was no effect on locomotor activity, novel object recognition and watermaze delayed-matching-to-place performance, T30 infusion reduced weight growth in the rats. Post mortem immunohistochemistry showed that T30 increased the AD biomarkers amyloid beta and phosphorylated tau in the cortex, hippocampus, and midbrain. Significant neuronal loss, indicated by reduced NeuN staining, was observed in brain tissue pooled from neocortex, hippocampus and midbrain. Further analysis showed a strong correlation between the 14mer T14, the active component of T30, and levels of its parent molecule acetylcholinesterase. However, this correlation only applied to protein levels, not enzymatic activity, suggesting independence from cholinergic transmission. Together, these findings support a non-cholinergic, peptide-driven mechanism by which T30 contributes to Alzheimer's-like neurodegeneration.

Neurochemical research 2026 Oct 31 PubMed
23 Revealing Pharmacological Target for Comorbid Epilepsy in Alzheimer's Disease: Neurochemical Insights from STZ Mice. Kaur A et al. 10.1007/s11064-026-04947-9
View abstract

Despite growing evidences of shared neurochemical alterations linked to comorbid epilepsy in AD, effective unified therapeutic strategies remain lacking. Thus, the present investigation was designed to identify shared neurochemical changes associated with lowered convulsive threshold in STZ (streptozotocin) model of AD-type dementia to pharmacologically address this comorbidity. Swiss albino mice were injected STZ (3 mg/kg, ICV) to induce AD-like pathology. On day 22nd, STZ mice were divided into two groups: one group served as AD control (STZ) and another group (STZ + PTZ) received PTZ (35 mg/kg) kindling to assess the reduced epileptogenesis threshold while naïve served as negative control. One more group was involved as epileptic control (PTZ). All groups underwent behavioral assessment using elevated plus maze, novel object recognition test and radial arm maze. Mice were euthanized on day 48th to collect the brain samples. The brain homogenate was used to assess redox status (GSH, TBARS and ROS), acetylcholinesterase (AChE) activity, amyloid and tau protein expression, histological alterations for specific disease pathology. As well as for neurochemical analysis to assess the shared neurochemical targets associated with comorbid epilepsy in AD. STZ mice were subjected to PTZ kindling exhibited significant greater seizure severity. The kindled status achieved by the sixth injection of PTZ, indicating reduced epileptogenic threshold. Behavioural results indicated significant cognitive impairment in STZ + PTZ treated mice compared with naive mice in EPM, NORT and RAM test. Significantly increased oxidative stress and cholinergic dysfunctions observed in STZ + PTZ mice. Neurochemical analysis revealed augmented excitatory neurotransmitter levels, along with declined glycine, GABA, taurine and arginine in STZ + PTZ mice. Moreover, reduced levels of monoamines and their metabolites reflect cognitive deficits in STZ and STZ + PTZ mice. This increased susceptibility to seizures was accompanied by significantly increased oxidative stress and excitatory neurotransmission in STZ + PTZ mice. Collectively, these observations suggest that AD related neurodegeneration may predispose to epileptogenesis further aggravate neurochemical changes. Our findings suggest that taurine, arginine and monoamines may serve as a shared neurochemical target for comorbid epilepsy in AD-type dementia.

Neurochemical research 2026 Oct 31 PubMed
24 Leveraging immunoprecipitation mass spectrometry and neuropathology to identify the clinical value of different blood tau species in Alzheimer's disease. Labonte J et al. 10.1007/s00415-026-14232-y
View abstract

INTRODUCTION: Advances in plasma-based assays have allowed for the study of several tau and p-tau epitopes. P-tau217 has emerged as one of the most robust markers of Alzheimer's disease (AD) pathology. Despite their strong diagnostic performance, plasma tau biomarkers require further validation to clarify their clinical utility. OBJECTIVE: To investigate the associations between a panel of phosphorylated and non-phosphorylated tau species measured in antemortem plasma and clinical features of autopsy-confirmed AD. METHODS: Cross-sectional data from 123 participants from the BU ADRC who had antemortem blood draws and brain donation following death. Participants completed neuropsychological testing during life as part of their National Alzheimer's Coordinating Center-Uniform Data Set (NACC UDS) evaluation. AD neuropathology was diagnosed using NIA-Reagan criteria. Time interval between testing at last visit and autopsy ranged from 0 to 12 years, mean = 5.54 years. Raw neuropsychological test scores were used for analysis. Sample size ranged from 65 to 91 across the tests. Plasma samples were analyzed using immunoprecipitation mass spectrometry (IP-MS) for phosphorylated tau species (p-tau-181, 199, 202, 205, 217, 231) and non-phosphorylated tau (195-209, 212-221) peptides. Two ratios were analyzed, p-tau217/tau212-221 and p-tau205/tau195-209. RESULTS: 123 participants took part in this study, 55 (44.7%) female, and 6 (4.9%) Black/African American. The mean (SD) age at blood draw was 78.17 (8.55). The strongest association between plasma biomarkers with neuropsychological test outcomes was observed with the ratio p-tau217/tau212-221 (b = - 0.564-0.404, p = 0.00-0.18), followed by p-tau217 (b = - 0.478-0.377, p = 0.00-0.28), both significantly correlating with six of the eight neuropsychological measures (p < 0.05). Followed by the ratio p-tau205/tau195-209 (b = - 0.513-0.356, p = 0.00-0.55), p-tau205 (b = - 0.365-0.226, p = 0.00-0.44), then p-tau231 (b = - 0.319-0.237, p = 0.02-0.62). Fewer significant relationships and weaker effect sizes were observed among the other biomarkers. The effect sizes of the ratio p-tau217/tau212-221, followed closely by p-tau217 on neuropsychological test outcomes, were observed to be the most similar to the effect sizes of autopsy-confirmed AD (b = - 0.564-0.393). CONCLUSIONS: Plasma p-tau217 and p-tau ratios were comparable to autopsy-confirmed AD in predicting clinical outcomes of AD. This study highlights the promise and potential utility of plasma biomarkers for symptom monitoring.

Journal of neurology 2026 Oct 31 PubMed
25 AI-based diagnosis of frontotemporal dementia using neuroimaging: a systematic review and meta-analysis. Li Y et al. 10.1007/s00330-026-13016-2
View abstract

OBJECTIVE: This meta-analysis aimed to evaluate the diagnostic accuracy of neuroimaging-based artificial intelligence (AI) models for detecting frontotemporal dementia (FTD) and its primary clinical subtypes. MATERIALS AND METHODS: A systematic search of PubMed, Embase, Web of Science, and Cochrane Library was conducted up to October 22, 2025. Studies reporting neuroimaging-based AI model performance for diagnosing FTD variants against cognitively normal (CN) controls were included. Study quality and outcome certainty were assessed using the PROBAST + AI tool and GRADE. A bivariate random-effects model was used to calculate pooled sensitivity, specificity, and the area under the curve (AUC). RESULTS: Twenty-three studies involving 3670 subjects were included. AI models demonstrated a pooled sensitivity of 0.91 (95% CI: 0.87-0.93; I = 73.2%), specificity of 0.92 (95% CI: 0.89-0.94; I = 80.2%), and an AUC of 0.96 (95% CI: 0.94-0.98). Subtype analysis revealed the highest performance for semantic variant primary progressive aphasia (svPPA), with an AUC of 0.98 (95% CI: 0.97-0.99). Across neuroimaging modalities (sMRI, fMRI, PET, and multimodal), AUC values remained consistently robust, ranging from 0.94 to 0.98. Notably, a temporal analysis indicated a slight declining trend in reported AUC values from 2009 to 2025, though most models maintained an AUC above 0.90. CONCLUSIONS: Neuroimaging-based AI models show promising diagnostic performance for FTD, especially for the svPPA subtype, supporting their potential as a clinical adjunct. However, the evidence certainty is limited by frequent high risk of bias and study heterogeneity. Prospective, multicenter validation is required to confirm generalizability and clinical utility. REGISTRATION NUMBER: CRD420251270006. KEY POINTS: Question Can neuroimaging-based artificial intelligence accurately distinguish frontotemporal dementia and its major clinical subtypes from cognitively normal controls in published diagnostic studies? Findings Across 23 studies, pooled accuracy was high, but estimates were limited by heterogeneity, small subgroup samples, and frequent validation bias. Clinical relevance AI models may support FTD diagnostic workflows, but current evidence favors cautious adjunctive use rather than stand-alone clinical implementation until prospective external validation improves.

European radiology 2026 Oct 31 PubMed
26 Undiagnosed dementia in underserved African American populations: Missed opportunities for care. G. Cohen et al. 10.1016/j.inpsyc.2026.100208 International psychogeriatrics 2026 Scholar
27 Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation Chuo-Yu Lee et al. 10.1186/s13195-026-02095-4 Alzheimer's Research & Therapy 2026 Scholar
28 Biopsychosocial risk factors for Alzheimer’s disease and related dementias in UK immigrants from the Middle East and North Africa (MENA) Elizabeth Haddad et al. 10.64898/2026.05.08.26352762 medRxiv 2026 Scholar
29 Decreased Length of Locus Coeruleus Norepinephrine Axons and Increased Amyloid Beta Pathology in Male APP/PS1 Mice During Protracted Abstinence From Alcohol Ivy J. Z. Garland et al. 10.1007/s12640-026-00794-2 Neurotoxicity Research 2026 Scholar
30 Causes of death in patients with dementia: A study in a geriatric hospital in São Paulo, Brazil Yngrid Dieguez Ferreira et al. 10.1177/13872877261445578 Journal of Alzheimer's Disease 2026 Scholar
31 Annual Wellness Visits and Timing of Advance Care Planning Among Medicare Beneficiaries With Cognitive Impairment Zhiwei Hu et al. 10.1111/jgs.70368 2 citations Journal of the American Geriatrics Society 2026 Scholar
32 DNA Origami-Based Aptamers Targeting the Beta-secretase 1 (BACE1) Protein in Alzheimer’s Disease Yashasvi Kompella et al. 10.1109/ICHI69079.2026.00168 2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) 2026 Scholar
33 Neuroinflammation in Alzheimer’s disease-associated sensory dysfunction: mechanistic links, actionable targets and therapeutic strategies Yanjiao Xu et al. 10.3389/fnagi.2026.1838634 Frontiers in Aging Neuroscience 2026 Scholar
34 AI-Driven Detection of Alzheimer's Disease: Deep Learning for Identifying Four Stages of Dementia K. S. Manojee et al. 10.1109/ICICCS67901.2026.11502853 2026 9th International Conference on Intelligent Computing and Control Systems (ICICCS) 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Dementia & Alzheimer's
  • Week: October 26 – November 2, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 6:20 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —